Abstract:Background:: In the last years, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused more than 760 million infections and 6.9 million deaths. Currently, remains a public health problem with limited pharmacological treatments. Among the virus drug targets, the SARS-CoV-2 spike protein attracts the development of new anti-SARS-CoV-2 agents. background: In the last years, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused more than 760 million infections and 6.9 million of deaths. Currently, remains as a public health problem with limited pharmacological treatments. Among the virus drug targets, the SARS-CoV-2 spike protein follow be attractive for the development of new anti-SARS-CoV-2 agents. Objective:: The aim of this work was to identify new compounds derived from natural products (BIOFACQUIM and Selleckchem databases) as potential inhibitors of the spike receptor binding domain (RBD)-ACE2h binding complex. objective: The aim of this work was to identify new compounds derived from natural products (BIOFACQUIM and Selleckchem databases) as potential inhibitors of spike receptor binding domain (RBD)-ACE2h binding complex. Methods:: Molecular docking, molecular dynamics simulations, and ADME-Tox analysis were performed to screen and select the potential inhibitors. ELISA-based enzyme assay was done to confirm our predictive model. method: Molecular docking, molecular dynamics simulations, and ADME-Tox analysis were performed to screen and select the potential inhibitors. ELISA-based enzyme assay was done to confirm our predictive model. Results:: Twenty compounds were identified as potential binders of RBD of the spike protein. In vitro assay showed compound B-8 caused 48% inhibition at 50 μM, and their binding pattern exhibited interactions via hydrogen bonds with the key amino acid residues present on the RBD. result: Twenty compounds were identified as potential binders of RBD of the spike protein. In vitro assay showed compound B-8 cause 48% of inhibition at 50 μM and their binding pattern exhibited interactions via hydrogen bonds with the key amino acid residues present on the RBD. Conclusion:: Compound B-8 can be used as a scaffold to develop new and more efficient antiviral drugs. conclusion: Compound B-8 can be used as a scaffold to develop new and more efficient antiviral drugs. other: None

The Study of Antiviral Drugs Targeting SARS-CoV-2 Nucleocapsid and Spike Proteins Through Large-Scale Compound Repurposing.

A Search for Medications to Treat COVID-19 Via in Silico Molecular Docking Models of the SARS-CoV-2 Spike Glycoprotein and 3CL Protease

Computational View Toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease.

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs

Potential Clinical Drugs As Covalent Inhibitors of the Priming Proteases of the Spike Protein of SARS-CoV-2

Viroinformatics-based investigation of SARS-CoV-2 core proteins for potential therapeutic targets

Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein

Discovery of Novel Spike Inhibitors against SARS-CoV-2 Infection

Drug Repurposing to find Inhibitors of SARS-CoV-2 Main Protease

Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development

Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus

Virtual screening FDA approved drugs against multiple targets of SARS-CoV-2

Structure-based Virtual Screening from Natural Products as Inhibitors of SARS-CoV-2 Spike Protein and ACE2-h Receptor Binding and their Biological Evaluation In vitro

Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2

Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening

Identification of potential antiviral compounds against SARS-CoV-2 structural and non structural protein targets: A pharmacoinformatics study of the CAS COVID-19 dataset

Potential Inhibitors for Targeting Mpro and Spike of SARS-CoV-2 Based on Sequence and Structural Pharmacology Analysis

Structure-Based Virtual Screening and Identification of Potential Inhibitors of SARS-CoV-2 S-RBD and ACE2 Interaction

Drug repurposing for SARS-CoV-2: a high-throughput molecular docking, molecular dynamics, machine learning, and DFT study

Systematic virtual screening in search of SARS CoV-2 inhibitors against spike glycoprotein: pharmacophore screening, molecular docking, ADMET analysis and MD simulations